SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines

ERK-Dependent Bim Modulation Downstream of the 4-1BB-TRAF1 Signaling Axis Is a Critical Mediator of CD8 T Cell Survival In Vivo

(2014) L. Sabbagh et al.   JOURNAL OF IMMUNOLOGY

TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells

(2013) Ryan M. Stephenson et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Key Regulators of Sensitization and Tolerance: GM-CSF, IL-10, TGF-β and the Notch Signaling Pathway in Adjuvant-Free Experimental Models of Respiratory Allergy

(2013) George V. Guibas et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

(2013) Yared Hailemichael et al.   NATURE MEDICINE

CD4+ T Cells Play a Critical Role in the Generation of Primary and Memory Antitumor Immune Responses Elicited by SA-4-1BBL and TAA-Based Vaccines in Mouse Tumor Models

(2013) Rajesh K. Sharma et al.   PLoS One

Trial Watch

(2013) Erika Vacchelli et al.   OncoImmunology

CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells

(2012) Álvaro Teijeira et al.   FASEB JOURNAL

Intratumoral Injection of CpG Oligonucleotides Induces the Differentiation and Reduces the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells

(2012) Y. Shirota et al.   JOURNAL OF IMMUNOLOGY

SA-4-1BBL Costimulation Inhibits Conversion of Conventional CD4+ T Cells into CD4+FoxP3+ T Regulatory Cells by Production of IFN-γ

(2012) Shravan Madireddi et al.   PLoS One

Prime-Boost Vaccination with SA-4-1BBL Costimulatory Molecule and Survivin Eradicates Lung Carcinoma in CD8+ T and NK Cell Dependent Manner

(2012) Abhishek K. Srivastava et al.   PLoS One

Host CD25+CD4+Foxp3+ Regulatory T Cells Primed by anti-CD137 mAbs Inhibit Graft-versus-Host Disease

(2011) Juyang Kim et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines

(2011) Marijo Bilusic et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

(2011) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Science gone translational: the OX40 agonist story

(2011) Andrew D. Weinberg et al.   IMMUNOLOGICAL REVIEWS

Cancer immunotherapy – revisited

(2011) W. Joost Lesterhuis et al.   NATURE REVIEWS DRUG DISCOVERY

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

(2011) Michael A. Curran et al.   PLoS One

Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody

(2010) C. Cheong et al.   BLOOD

Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy

(2010) R K Sharma et al.   CANCER GENE THERAPY

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

(2010) Juan Dubrot et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

4-1BB Ligand as an Effective Multifunctional Immunomodulator and Antigen Delivery Vehicle for the Development of Therapeutic Cancer Vaccines

(2010) R. K. Sharma et al.   CANCER RESEARCH

Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children

(2010) M. Rosewich et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Naive tumor-specific CD4+T cells differentiated in vivo eradicate established melanoma

(2010) Ying Xie et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model

(2010) Rajesh K. Sharma et al.   VACCINE

Costimulation as a Platform for the Development of Vaccines: A Peptide-Based Vaccine Containing a Novel Form of 4-1BB Ligand Eradicates Established Tumors

(2009) R. K. Sharma et al.   CANCER RESEARCH

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

4-1BBL costimulation retrieves CD28 expression in activated T cells

(2009) Mojtaba Habib-Agahi et al.   CELLULAR IMMUNOLOGY

A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling

(2009) Songwen Ju et al.   INTERNATIONAL IMMUNOLOGY

Hypercostimulation through 4-1BB Distorts Homeostasis of Immune Cells

(2009) S.-W. Lee et al.   JOURNAL OF IMMUNOLOGY

4-1BB Functions As a Survival Factor in Dendritic Cells

(2009) B. K. Choi et al.   JOURNAL OF IMMUNOLOGY

Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy

(2009) Y. H. Kim et al.   MOLECULAR CANCER THERAPEUTICS

A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity

(2009) Rich-Henry Schabowsky et al.   VACCINE

Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies

(2008) Ignacio Melero et al.   TRENDS IN PHARMACOLOGICAL SCIENCES